Literature DB >> 8243377

The Lennox-Gastaut syndrome.

O Dulac1, T N'Guyen.   

Abstract

One of the most challenging areas in nosology is in the field of severe generalized epilepsy of early childhood. This is certainly true in the case of Lennox-Gastaut syndrome (LGS), an age-related epileptogenic encephalopathy which comprises several types of generalized seizures including tonic seizures, atypical absence seizures and frequent status epilepticus. EEG shows generalized slow spike waves, and as the disease progresses, cognitive functions deteriorate. LGS is listed in the 1989 classification of the International League Against Epilepsy alongside epilepsy with myoclonic astatic seizures and West's syndrome. A number of variants or atypical forms have been proposed. As a result, differential diagnosis presents a major challenge and includes specific generalized epilepsies, i.e., metabolic or inflammatory; secondarily generalized epilepsies, i.e., those arising from the frontal lobe; and severe forms of idiopathic generalized epilepsy, i.e., Doose syndrome. Antiepileptic drug (AED) treatment of LGS has been disappointing. Results obtained from anterior callosotomy have been promising, but only a small number of patients have been evaluated. Although the syndrome is rare, the severe nature and intractability of LGS emphasizes the need for the development of specific AEDs which would completely modify the quality of life for these patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8243377     DOI: 10.1111/j.1528-1157.1993.tb04593.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

1.  Networks underlying paroxysmal fast activity and slow spike and wave in Lennox-Gastaut syndrome.

Authors:  Neelan Pillay; John S Archer; Radwa A B Badawy; Danny F Flanagan; Samuel F Berkovic; Graeme Jackson
Journal:  Neurology       Date:  2013-07-17       Impact factor: 9.910

Review 2.  Medical management of Lennox-Gastaut syndrome.

Authors:  Aspasia Michoulas; Kevin Farrell
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 3.  A risk-benefit assessment of therapies for Lennox-Gastaut syndrome.

Authors:  D Schmidt; B Bourgeois
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

4.  De novo mutations in SIK1 cause a spectrum of developmental epilepsies.

Authors:  Jeanne Hansen; Chelsi Snow; Emily Tuttle; Dalia H Ghoneim; Chun-Song Yang; Adam Spencer; Sonya A Gunter; Christopher D Smyser; Christina A Gurnett; Marwan Shinawi; William B Dobyns; James Wheless; Marc W Halterman; Laura A Jansen; Bryce M Paschal; Alex R Paciorkowski
Journal:  Am J Hum Genet       Date:  2015-04-02       Impact factor: 11.025

5.  Focal abnormalities detected by 18FDG PET in epileptic encephalopathies.

Authors:  C D Ferrie; M Maisey; T Cox; C Polkey; S F Barrington; C P Panayiotopoulos; R O Robinson
Journal:  Arch Dis Child       Date:  1996-08       Impact factor: 3.791

Review 6.  Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.

Authors:  Rima Nabbout; Mathieu Kuchenbuch; Catherine Chiron; Paolo Curatolo
Journal:  CNS Drugs       Date:  2021-08-21       Impact factor: 5.749

Review 7.  Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox-Gastaut syndrome: a meta-analysis.

Authors:  Guido Lancman; Michael Virk; Huibo Shao; Madhu Mazumdar; Jeffrey P Greenfield; Steven Weinstein; Theodore H Schwartz
Journal:  Seizure       Date:  2012-10-12       Impact factor: 3.184

8.  Surgical treatment of patients with Lennox-Gastaut syndrome phenotype.

Authors:  Shi-Yong Liu; Ning An; Xiang Fang; Prabhdeep Singh; Joseph Oommen; Qing Yin; Mei-Hua Yang; Yong Liu; Wei Liao; Chang-Qing Gao; Hui Yang
Journal:  ScientificWorldJournal       Date:  2012-05-01

Review 9.  Conceptualizing lennox-gastaut syndrome as a secondary network epilepsy.

Authors:  John S Archer; Aaron E L Warren; Graeme D Jackson; David F Abbott
Journal:  Front Neurol       Date:  2014-10-30       Impact factor: 4.003

Review 10.  Lennox-Gastaut syndrome. Management update.

Authors:  Muradi H Al-Banji; Doaa K Zahr; Mohammed M Jan
Journal:  Neurosciences (Riyadh)       Date:  2015-07       Impact factor: 0.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.